Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma
Latest Information Update: 06 May 2024
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 08 Feb 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2026.
- 08 Feb 2023 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2026.
- 08 Feb 2023 Planned initiation date changed from 25 Nov 2020 to 15 Feb 2023.